Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"Immune checkpoint inhibitor"”.
-
Outcomes of Immune Checkpoint Inhibitor-Mediated Colitis: Multicenter Cohort Study
Immune checkpoint inhibitor (ICI)-mediated colitis (IMC) is a common and serious toxicity. Multiple reports have described the clinical presentation and course of IMC based on limited data. This was a collaborative effort from several cancer institutes to investigate features and outcomes of IMC. …
-
Investigating the role of the gut microbiota on immune checkpoint inhibitor-mediated colitis
<p>Immune checkpoint inhibitors (ICIs) have been revolutionary in the fight against cancer by recruiting the host immune system as an agent for attack on malignant cells. Unfortunately, immune-related adverse events (irAEs), including ICI-mediated colitis (IMC), are common side effects that result …
-
Modulating the gut microbiome to improve immune checkpoint inhibitor response to cancer: current therapies and emerging methods
… surgery, chemotherapy, and radiotherapy. Immune checkpoint inhibitor (ICI) therapy is an immunotherapy that blocks inhibitory immune checkpoint interactions, allowing T cells and other immune cells to kill tumor cells. In the tumor microenvironment, there is often overexpression of immune …
-
From Oncogenesis to Immunotherapy: Mathematical Modeling of Heterogeneous Cancers
… conditions in a dynamical systems model of tumor-immune interactions, parameterized using clinical trial data, we characterize features associated with a durable response to immune checkpoint inhibitor (ICI) immunotherapy in MMR-D CRC.
-
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
… developed the highly selective and potent CDK9 inhibitor MC180295 (IC50 =5nM) that has broad anti-cancer activity in-vitro and is effective in in-vivo cancer models. Additionally, CDK9 inhibition sensitizes with the immune checkpoint inhibitor α-PD-1 in vivo, making it an excellent target for …
-
DISSECTING RESISTANCE TO IMMUNOTHERAPY IN MSS COLORECTAL CANCER
… (MSI) often display favorable responses to immune checkpoint inhibitor (ICI) therapies, in contrast to mismatch repair proficient and microsatellite stable (MSS) tumors. While the high mutational burden and elevated neoantigen levels in MSI CRCs are recognized as key determinants of ICI …
-
Identification of MEN1 loss-off function as a potential biomarker for immune checkpoint therapy
Immune-based therapies are an emerging field in the treatment of cancers, with immune checkpoint inhibitor therapies proving to be particularly effective, even in typically hard to treat cancers. Despite effective immune checkpoint therapies now being available, it is still difficult to predict …
-
Single-cell Functional Profiling of Lymphocytes for Cancer Immunotherapy
Immunotherapy by harnessing patients’ the immune system has changed the landscape of cancer therapeutics and shown promising and remarkable clinical responses. However, not all the patients would be beneficial from the treatment. Lymphocytes are a significant target in anti-tumor immunotherapy, and …
-
Application of Informatics Tools to Facilitate the Practice of Precision Medicine with Genomic Testing and Clinical Data
… on non-small cell lung cancer patients receiving immune checkpoint inhibitor (ICI) therapy. Through multivariate statistical models and vi survival analyses, we demonstrated the impact of various clinical and biomolecular variables on patient survival. Our results showed patients experiencing …
-
Role of the Gut Microbiome in Cancer Immunotherapy Efficacy and Side Effects
… various physiological processes, including immune responses. Its role becomes particularly significant in cancer immunotherapy, where the microbiome can shape both the efficacy and side effects of immune checkpoint inhibitor (ICI) therapies. However, the intricate interactions between …
-
Generation and in vivo validation of multi-functional antibody-fusion proteins for cancer therapy
… treatment, introducing novel strategies such as checkpoint inhibitors, antibody-drug conjugates, and CAR-T cell therapies. Recombinant cytokines have been explored for decades in cancer treatment, but only some patients benefit from their administration. The major drawback of recombinant …
-
Regulation of the cGAS-STING Pathway: Non-Agonist Activation and Cellular Trafficking
The cGAS-STING pathway in the innate immune system plays an important role in infection and cancer. Exogenous or endogenous DNA and cyclic dinucleotides acutely activate cGAS-STING, leading to type I interferon (IFN) signaling. STING-mediated IFN signaling is dynamically regulated by STING …
-
Discovery of IKBKE and CD24 siRNAs for the treatment of triple-negative breast cancer
… anti-PD-L1 human domain antibody as an immune checkpoint inhibitor for cancer immunotherapy. In Chapter 1, we briefly introduced the background of the research, the statement of the problems, and research objectives. In Chapter 2, we reviewed potential treatment options for TNBC and …
-
Development and evaluation of methodologies for analysis of CTC and ctDNA in patients with ovarian carcinoma
… in a neoadjuvant chemotherapy (NACT) plus immune checkpoint inhibitor clinical trial (iPRIME, ACTRN12618000109202) (Chapter 5). Cell free DNA (cfDNA) was sequenced using the Oncomine™ Breast cfDNA Research Assay V2, and selected mutations were validated using droplet digital PCR (ddPCR). …